Hemodynamic-GUIDEd Management of Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2358 participants.

Also called NCT03387813

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,358 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03387813
Other papers using this trial's data
  • Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides JACC. Heart failure, 2023-06 DOI, PubMed 37286262

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03387813. Randomized; single masking; primary purpose treatment. Start 2018-03-15 (actual); primary completion 2023-05-17 (actual). Results posted on 2025-08-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hemodynamic-GUIDEd Management of Heart Failure
Acronym
GUIDE-HF
Condition
Heart Failure
Condition
Heart Failure, Systolic
Condition
Heart Failure, Diastolic
Condition
Heart Failure NYHA Class II
Condition
Heart Failure NYHA Class III
Condition
Heart Failure NYHA Class IV
Condition
Heart Failure,Congestive
Condition
Heart Failure With Normal Ejection Fraction
Condition
Heart Failure; With Decompensation
Intervention (Device)
CardioMEMS™ HF System
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03387813
Content hash
6a6db8658797ab571cf62cab0fc2240050b2c281870d59ad3fbd913b4250d3f2